Marburg Virus Disease Therapeutics Market by Drug Classification, Route of Administration, End Users, Distribution Channel, Region | Forecast 2023 to 2033
Market Insights on Marburg Virus Disease Therapeutics covering sales outlook, demand forecast and up-to-date key trends
Marburg Virus Disease Therapeutics Market Snapshot (2023 to 2033)
The global Marburg virus disease therapeutics market is expected to garner a market value of US$ 90.74 Million in 2023 and is expected to accumulate a market value of US$ 155 Million by registering a CAGR of 5.5% in the forecast period 2023 to 2033. The growth of the Marburg virus disease therapeutics market can be attributed to the increasing prevalence of the Marburg virus in different geographical regions. The demand for Marburg virus disease therapeutics registered a CAGR of 4.1% in the historical period 2018 to 2022
The Marburg virus disease market is expected to witness growth owing to the increasing prevalence of the ailment. In addition, the COVID-19 virus is fueling research and development activities for innovating therapeutics treatment for the Marburg virus diseases therapeutics market.
Data Points
Key Statistics
Expected Market Value (2023)
US$ 90.74 Million
Anticipated Forecast Value (2033)
US$ 155 Million
Projected Growth Rate (2023 to 2033)
5.5% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Marburg Virus Disease Therapeutics Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Marburg virus disease therapeutics reflected a value CAGR of 4.1% during the historic period, 2018 to 2022.
The similar symptoms of COVID-19 and Marburg virus diseases have created tremendous pressure on the healthcare industries, especially in the Middle East and South Africa. Thus, the demand for innovative treatments to reduce the intensity of the viruses is expected to boost the overall market in the upcoming years.
Furthermore, extensive research and development for innovating therapeutics are favoring the market's growth. Thus, the Marburg virus disease therapeutics market is expected to register a CAGR of 5.5% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Marburg Virus Disease Therapeutics Market?
Exposure to the Marburg virus increases cases of contracting the virus among people
The rise in the healthcare sector globally is escalating the growth of the Marburg virus disease market. Marburg virus refers to the type of virus that belongs to the genus Marburgvirus in the family Filoviridae. This virus causes a severe viral disease that is known as Marburg virus disease (MHF), in both humans and nonhuman primates. MHF is generally characterized by systemic viral replication, abnormal inflammatory responses, and immunosuppression, similar to the Ebola virus.
Marburg can spread through human-to-human transmission via direct contact (through broken skin or mucous membranes) with the blood, secretions, organs, or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, and clothing) contaminated with these fluids. Thus, these factors are increasing the cases of the Marburg virus disease across the globe.
Increase in the prevalence of unhealthy lifestyles along with research and development efforts contributing to market growth
The surge in the number of people suffering from Marburg virus disease across the globe is one of the major factors driving the growth of the Marburg virus disease market. The rise in awareness among people regarding rare disorders and increased demand for various drugs for treating symptoms such as nausea, vomiting, chest pain, diarrhea, and jaundice, among others accelerate the market growth.
The rise in the number of clinical trials for the enhancement of drugs and therapies and the increase in the prevalence of unhealthy lifestyles of people further influence the market. Additionally, growth in awareness, the surge in investments, development in technology, change in lifestyle and rise in healthcare expenditure positively affect the Marburg virus disease market. Furthermore, advancements in medications extend profitable opportunities to the market players in the forecast period of 2023 to 2033.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Marburg Virus Disease Therapeutics Market?
Lack of awareness amongst people and the expensive nature of treatment derailing market growth
On the other hand, the high cost associated with the treatment and diagnosis is expected to obstruct market growth. Moreover, the expenditure required for investing in research and development for innovating therapeutics for treating the Marburg virus is more. This, in turn, is hampering the growth of the market.
Low awareness among people is projected to challenge the Marburg virus disease market in 2023 to 2023. Thus. Late detection of the ailment reduces the chances of receiving proper treatment to cure the ailment. All these factors are creating obstacles to the growth of the Marburg virus diseases therapeutics market.
Region-Wise Insights
Improved Healthcare Infrastructure Boosting Therapeutics Treatment for Marburg Viral Diseases Therapeutics Treatment in North America?
Investment in research and development by key players favoring the market growth
North America dominates the Marburg virus disease market due to the advanced medical care system and infrastructure within the region. Moreover, the increasing prevalence of Marburg viral diseases in the region is bolstering the need for therapeutics.
Furthermore, the strong presence of key players in the region is favoring the growth of the market. Investment in research and development to innovate novel therapeutic treatment is another factor driving the growth of the market. the presence of research institutes in the USA. and Canada is bolstering the growth of the Marburg virus diseases therapeutics market in North America. Thus, North America is expected to possess a 43% market share of the Marburg virus diseases therapeutics market in North America in 2023.
Increasing Prevalence of Marburg Virus Diseases in the Middle East and South Africa Creating Lucrative Opportunities for Therapeutics Treatment?
Absence of Vaccines increasing dependability on Therapeutics Treatment
Owing to the increasing predominance of Ebola Virus Disease (EVD) or Ebola Virus disease and Marburg Virus Disease (MVD) or Marburg Virus disease, caused by filoviruses termed Ebola virus and Marburg virus in African countries like Guinea, the Democratic Republic of the Congo, Uganda, Angola, Kenya, and South Africa, as per updates by World Health Organization (WHO), in the Rest of the world region.
Ebola & Marburg Infections market growth is being driven by the increasing Ebola outbreaks in Guinea which then spread to Sierra Leone and Liberia and cases of Marburg Virus Disease (MVD) in Uganda and Angola. The Democratic Republic of the Congo, Kenya, and South Africa. However, as per World Health Organization (WHO), presently, there are no vaccines or antiviral treatments certified for Marburg Virus Disease (MVD) or Marburg Virus disease, which is one of the major factors hampering the growth of the Ebola & Marburg Infections Market. Thus, the Middle East and Africa are expected to possess a 39% market share for Marburg viral disease therapeutic treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Availability of Various Treatments Making Hospitals Convenient for Treatment for Marburg Virus Disease Therapeutics Market?
Favorable reimbursement policies make hospitals a viable option for treatment
On the basis of end users, the Marburg virus diseases market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centres, and Others. The hospital segment is expected to hold the largest market share for Marburg virus disease therapeutics. This is owing to the availability of various treatments and diagnostics in hospitals. In addition, the presence of healthcare experts and cardiologists plays a key role in the wide usage of hospitals for the treatment of Marburg virus disease therapeutics.
In addition, initiatives by government authorities to support the treatment of Marburg virus disease therapeutics, especially in hospitals, favor the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of Marburg virus disease therapeutics. Thus, the hospital segment is expected to hold a 45% market share of the Marburg virus disease therapeutics market in 2023.
Market Competition
Key players in the Marburg virus disease therapeutics market are Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, BioCryst Pharmaceuticals, Bavarian Nordic, Bio-Rad Laboratories, Inc, AlphaVax, GW Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, Alexion Pharmaceuticals, Inc, Mapp Biopharmaceutical, Collaborations Pharmaceuticals, Inc, Emergent BioSolutions Inc, BioMarin and Sarepta Therapeutics, Alkido Pharma, Biofactura
BioCryst Pharmaceuticals, a key player in the Marburg virus disease therapeutics market is focusing on undertaking research and development for understanding the nature of the virus and innovating therapeutic treatments for the same.
Bio-Rad Laboratories, Inc, another key player in the Marburg virus disease therapeutics market is integrating technology to understand the ailment and offering medication for treating the virus.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 90.74 Million
Market Value in 2033
US$ 155 Million
Growth Rate
CAGR of 5.5% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2017 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Drug Classification
Route of Administration
End Users
Distribution Channel
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
The USA
Canada
Brazil
Mexico
Germany
The United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Amicus Therapeutics Inc.
Alexion Pharmaceuticals Inc.
BioCryst Pharmaceuticals
Bavarian Nordic
Bio-Rad Laboratories, Inc.
AlphaVax
GW Pharmaceuticals Plc
Takeda Pharmaceutical Company Limited
Mapp Biopharmaceutical
Collaborations Pharmaceuticals Inc.
Emergent BioSolutions Inc.
BioMarin and Sarepta Therapeutics
Alkido Pharma
Biofactura
Key Segments Profiled in the Marburg Virus Disease Therapeutics Industry Survey
By Drug Classification:
Antiemetic
Nitro-glycerine
Loperamide
Antibiotics
Others
By Route of Administration:
Injectable
Oral
Parenteral
By End Users:
Hospitals
Specialty Clinics
Ambulatory Surgical Centres
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Frequently Asked Questions
What is the Current Market Valuation?
The marburg virus disease therapeutics market is valued at US$ 90.74 million In 2023.
What is the Expected Market Growth Rate until 2033?
The market is likely to experience a 5.5% CAGR until 2033.
Which End-user segment is Likely to Dominate the market until 2033?
The hospital segment is expected to dominate the market based on end user.
How is the Historical Performance of the Market?
The market registered a CAGR of 4.1% from 2018 to 2022.
Which Region is Estimated to Dominate the Market through 2033?
North America is estimated to dominate the market through 2033.
Table of Content
1. Executive Summary | Marburg Virus Disease Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Classification
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) Analysis By Drug Classification, 2018 to 2022
5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Classification, 2023 to 2033
5.3.1. Antiemetic
5.3.2. Nitro-glycerine
5.3.3. Loperamide
5.3.4. Antibiotics
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Classification, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Classification, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Injectable
6.3.2. Oral
6.3.3. Parenteral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) Analysis By End-Users, 2018 to 2022
7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End-Users, 2023 to 2033
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Ambulatory Surgical Centres
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End-Users, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End-Users, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The USA
10.2.1.2. Canada
10.2.2. By Drug Classification
10.2.3. By Route of Administration
10.2.4. By End-Users
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Classification
10.3.3. By Route of Administration
10.3.4. By End-Users
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Classification
11.2.3. By Route of Administration
11.2.4. By End-Users
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Classification
11.3.3. By Route of Administration
11.3.4. By End-Users
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. The United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Classification
12.2.3. By Route of Administration
12.2.4. By End-Users
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Classification
12.3.3. By Route of Administration
12.3.4. By End-Users
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Classification
13.2.3. By Route of Administration
13.2.4. By End-Users
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Classification
13.3.3. By Route of Administration
13.3.4. By End-Users
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Classification
14.2.3. By Route of Administration
14.2.4. By End-Users
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Classification
14.3.3. By Route of Administration
14.3.4. By End-Users
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Classification
15.2.3. By Route of Administration
15.2.4. By End-Users
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Classification
15.3.3. By Route of Administration
15.3.4. By End-Users
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Classification
16.2.3. By Route of Administration
16.2.4. By End-Users
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Classification
16.3.3. By Route of Administration
16.3.4. By End-Users
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. The USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Classification
17.1.2.2. By Route of Administration
17.1.2.3. By End-Users
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Classification
17.2.2.2. By Route of Administration
17.2.2.3. By End-Users
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Classification
17.3.2.2. By Route of Administration
17.3.2.3. By End-Users
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Classification
17.4.2.2. By Route of Administration
17.4.2.3. By End-Users
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Classification
17.5.2.2. By Route of Administration
17.5.2.3. By End-Users
17.5.2.4. By Distribution Channel
17.6. The United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Classification
17.6.2.2. By Route of Administration
17.6.2.3. By End-Users
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Classification
17.7.2.2. By Route of Administration
17.7.2.3. By End-Users
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Classification
17.8.2.2. By Route of Administration
17.8.2.3. By End-Users
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Classification
17.9.2.2. By Route of Administration
17.9.2.3. By End-Users
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Classification
17.10.2.2. By Route of Administration
17.10.2.3. By End-Users
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Classification
17.11.2.2. By Route of Administration
17.11.2.3. By End-Users
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Classification
17.12.2.2. By Route of Administration
17.12.2.3. By End-Users
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Classification
17.13.2.2. By Route of Administration
17.13.2.3. By End-Users
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Classification
17.14.2.2. By Route of Administration
17.14.2.3. By End-Users
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Classification
17.15.2.2. By Route of Administration
17.15.2.3. By End-Users
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Classification
17.16.2.2. By Route of Administration
17.16.2.3. By End-Users
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Classification
17.17.2.2. By Route of Administration
17.17.2.3. By End-Users
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Classification
17.18.2.2. By Route of Administration
17.18.2.3. By End-Users
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Classification
17.19.2.2. By Route of Administration
17.19.2.3. By End-Users
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Classification
17.20.2.2. By Route of Administration
17.20.2.3. By End-Users
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Classification
17.21.2.2. By Route of Administration
17.21.2.3. By End-Users
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Classification
18.3.3. By Route of Administration
18.3.4. By End-Users
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Amicus Therapeutics, Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Alexion Pharmaceuticals, Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. BioCryst Pharmaceuticals
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Bavarian Nordic
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Bio-Rad Laboratories, Inc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. AlphaVax
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. GW Pharmaceuticals plc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Takeda Pharmaceutical Company Limited
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Alexion Pharmaceuticals, Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Mapp Biopharmaceutical
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Collaborations Pharmaceuticals, Inc.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Emergent BioSolutions Inc.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. BioMarin and Sarepta Therapeutics
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. Alkido Pharma
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.15. Biofactura
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
20. Assumptions & Acronyms Used21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ million) Forecast by Drug Classification, 2018 to 2033
Table 3: Global Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Market Value (US$ million) Forecast by End-Users, 2018 to 2033
Table 5: Global Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 6: North America Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 7: North America Market Value (US$ million) Forecast by Drug Classification, 2018 to 2033
Table 8: North America Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033
Table 9: North America Market Value (US$ million) Forecast by End-Users, 2018 to 2033
Table 10: North America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 11: Latin America Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 12: Latin America Market Value (US$ million) Forecast by Drug Classification, 2018 to 2033
Table 13: Latin America Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033
Table 14: Latin America Market Value (US$ million) Forecast by End-Users, 2018 to 2033
Table 15: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 16: Europe Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 17: Europe Market Value (US$ million) Forecast by Drug Classification, 2018 to 2033
Table 18: Europe Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033
Table 19: Europe Market Value (US$ million) Forecast by End-Users, 2018 to 2033
Table 20: Europe Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 21: South Asia Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 22: South Asia Market Value (US$ million) Forecast by Drug Classification, 2018 to 2033
Table 23: South Asia Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033
Table 24: South Asia Market Value (US$ million) Forecast by End-Users, 2018 to 2033
Table 25: South Asia Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 26: East Asia Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 27: East Asia Market Value (US$ million) Forecast by Drug Classification, 2018 to 2033
Table 28: East Asia Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033
Table 29: East Asia Market Value (US$ million) Forecast by End-Users, 2018 to 2033
Table 30: East Asia Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 31: Oceania Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 32: Oceania Market Value (US$ million) Forecast by Drug Classification, 2018 to 2033
Table 33: Oceania Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033
Table 34: Oceania Market Value (US$ million) Forecast by End-Users, 2018 to 2033
Table 35: Oceania Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Table 36: MEA Market Value (US$ million) Forecast by Country, 2018 to 2033
Table 37: MEA Market Value (US$ million) Forecast by Drug Classification, 2018 to 2033
Table 38: MEA Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033
Table 39: MEA Market Value (US$ million) Forecast by End-Users, 2018 to 2033
Table 40: MEA Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ million) by Drug Classification, 2023 to 2033
Figure 2: Global Market Value (US$ million) by Route of Administration, 2023 to 2033
Figure 3: Global Market Value (US$ million) by End-Users, 2023 to 2033
Figure 4: Global Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 5: Global Market Value (US$ million) by Region, 2023 to 2033
Figure 6: Global Market Value (US$ million) Analysis by Region, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Market Value (US$ million) Analysis by Drug Classification, 2018 to 2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Classification, 2023 to 2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Classification, 2023 to 2033
Figure 12: Global Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 15: Global Market Value (US$ million) Analysis by End-Users, 2018 to 2033
Figure 16: Global Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 18: Global Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 21: Global Market Attractiveness by Drug Classification, 2023 to 2033
Figure 22: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 23: Global Market Attractiveness by End-Users, 2023 to 2033
Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 25: Global Market Attractiveness by Region, 2023 to 2033
Figure 26: North America Market Value (US$ million) by Drug Classification, 2023 to 2033
Figure 27: North America Market Value (US$ million) by Route of Administration, 2023 to 2033
Figure 28: North America Market Value (US$ million) by End-Users, 2023 to 2033
Figure 29: North America Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 30: North America Market Value (US$ million) by Country, 2023 to 2033
Figure 31: North America Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Market Value (US$ million) Analysis by Drug Classification, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Classification, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Classification, 2023 to 2033
Figure 37: North America Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 40: North America Market Value (US$ million) Analysis by End-Users, 2018 to 2033
Figure 41: North America Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 43: North America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 46: North America Market Attractiveness by Drug Classification, 2023 to 2033
Figure 47: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 48: North America Market Attractiveness by End-Users, 2023 to 2033
Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 50: North America Market Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Market Value (US$ million) by Drug Classification, 2023 to 2033
Figure 52: Latin America Market Value (US$ million) by Route of Administration, 2023 to 2033
Figure 53: Latin America Market Value (US$ million) by End-Users, 2023 to 2033
Figure 54: Latin America Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 55: Latin America Market Value (US$ million) by Country, 2023 to 2033
Figure 56: Latin America Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Market Value (US$ million) Analysis by Drug Classification, 2018 to 2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Classification, 2023 to 2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Classification, 2023 to 2033
Figure 62: Latin America Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 65: Latin America Market Value (US$ million) Analysis by End-Users, 2018 to 2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 68: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 71: Latin America Market Attractiveness by Drug Classification, 2023 to 2033
Figure 72: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 73: Latin America Market Attractiveness by End-Users, 2023 to 2033
Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 76: Europe Market Value (US$ million) by Drug Classification, 2023 to 2033
Figure 77: Europe Market Value (US$ million) by Route of Administration, 2023 to 2033
Figure 78: Europe Market Value (US$ million) by End-Users, 2023 to 2033
Figure 79: Europe Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 80: Europe Market Value (US$ million) by Country, 2023 to 2033
Figure 81: Europe Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Market Value (US$ million) Analysis by Drug Classification, 2018 to 2033
Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Classification, 2023 to 2033
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Classification, 2023 to 2033
Figure 87: Europe Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033
Figure 88: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 90: Europe Market Value (US$ million) Analysis by End-Users, 2018 to 2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 93: Europe Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 96: Europe Market Attractiveness by Drug Classification, 2023 to 2033
Figure 97: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 98: Europe Market Attractiveness by End-Users, 2023 to 2033
Figure 99: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: South Asia Market Value (US$ million) by Drug Classification, 2023 to 2033
Figure 102: South Asia Market Value (US$ million) by Route of Administration, 2023 to 2033
Figure 103: South Asia Market Value (US$ million) by End-Users, 2023 to 2033
Figure 104: South Asia Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 105: South Asia Market Value (US$ million) by Country, 2023 to 2033
Figure 106: South Asia Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: South Asia Market Value (US$ million) Analysis by Drug Classification, 2018 to 2033
Figure 110: South Asia Market Value Share (%) and BPS Analysis by Drug Classification, 2023 to 2033
Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Drug Classification, 2023 to 2033
Figure 112: South Asia Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033
Figure 113: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 115: South Asia Market Value (US$ million) Analysis by End-Users, 2018 to 2033
Figure 116: South Asia Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 117: South Asia Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 118: South Asia Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 119: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 121: South Asia Market Attractiveness by Drug Classification, 2023 to 2033
Figure 122: South Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 123: South Asia Market Attractiveness by End-Users, 2023 to 2033
Figure 124: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 126: East Asia Market Value (US$ million) by Drug Classification, 2023 to 2033
Figure 127: East Asia Market Value (US$ million) by Route of Administration, 2023 to 2033
Figure 128: East Asia Market Value (US$ million) by End-Users, 2023 to 2033
Figure 129: East Asia Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 130: East Asia Market Value (US$ million) by Country, 2023 to 2033
Figure 131: East Asia Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: East Asia Market Value (US$ million) Analysis by Drug Classification, 2018 to 2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by Drug Classification, 2023 to 2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Drug Classification, 2023 to 2033
Figure 137: East Asia Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033
Figure 138: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 140: East Asia Market Value (US$ million) Analysis by End-Users, 2018 to 2033
Figure 141: East Asia Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 142: East Asia Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 143: East Asia Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 144: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 146: East Asia Market Attractiveness by Drug Classification, 2023 to 2033
Figure 147: East Asia Market Attractiveness by Route of Administration, 2023 to 2033
Figure 148: East Asia Market Attractiveness by End-Users, 2023 to 2033
Figure 149: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 151: Oceania Market Value (US$ million) by Drug Classification, 2023 to 2033
Figure 152: Oceania Market Value (US$ million) by Route of Administration, 2023 to 2033
Figure 153: Oceania Market Value (US$ million) by End-Users, 2023 to 2033
Figure 154: Oceania Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 155: Oceania Market Value (US$ million) by Country, 2023 to 2033
Figure 156: Oceania Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 159: Oceania Market Value (US$ million) Analysis by Drug Classification, 2018 to 2033
Figure 160: Oceania Market Value Share (%) and BPS Analysis by Drug Classification, 2023 to 2033
Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Drug Classification, 2023 to 2033
Figure 162: Oceania Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033
Figure 163: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 165: Oceania Market Value (US$ million) Analysis by End-Users, 2018 to 2033
Figure 166: Oceania Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 167: Oceania Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 168: Oceania Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 169: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 171: Oceania Market Attractiveness by Drug Classification, 2023 to 2033
Figure 172: Oceania Market Attractiveness by Route of Administration, 2023 to 2033
Figure 173: Oceania Market Attractiveness by End-Users, 2023 to 2033
Figure 174: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 176: MEA Market Value (US$ million) by Drug Classification, 2023 to 2033
Figure 177: MEA Market Value (US$ million) by Route of Administration, 2023 to 2033
Figure 178: MEA Market Value (US$ million) by End-Users, 2023 to 2033
Figure 179: MEA Market Value (US$ million) by Distribution Channel, 2023 to 2033
Figure 180: MEA Market Value (US$ million) by Country, 2023 to 2033
Figure 181: MEA Market Value (US$ million) Analysis by Country, 2018 to 2033
Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 184: MEA Market Value (US$ million) Analysis by Drug Classification, 2018 to 2033
Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Classification, 2023 to 2033
Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Classification, 2023 to 2033
Figure 187: MEA Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033
Figure 188: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 189: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 190: MEA Market Value (US$ million) Analysis by End-Users, 2018 to 2033
Figure 191: MEA Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033
Figure 192: MEA Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033
Figure 193: MEA Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033
Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 196: MEA Market Attractiveness by Drug Classification, 2023 to 2033
Figure 197: MEA Market Attractiveness by Route of Administration, 2023 to 2033
Figure 198: MEA Market Attractiveness by End-Users, 2023 to 2033
Figure 199: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 200: MEA Market Attractiveness by Country, 2023 to 2033
